Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.63 |
| ▸ | NPY1R | P25929 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | GLP1R | P43220 | 13/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | MC5R | P33032 | 1/20 | 0.58 |
| ▸ | MC3R | P41968 | 1/20 | 0.58 |
| ▸ | MC1R | Q01726 | 1/20 | 0.58 |
| ▸ | GCGR | P47871 | 3/20 | 0.57 |
| ▸ | GIPR | P48546 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30843895 | 0.89 | NPY1R (0.69) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL30843897 | 0.88 | NPY1R (0.64) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL30578713 | 0.88 | C5AR1 (0.73) | C5AR1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30658215 | 0.88 | NPY1R (0.72) | C5AR1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30261957 | 0.87 | C5AR1 (0.68) | C5AR1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30906456 | 0.87 | NPY1R (0.67) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL29428971 | 0.87 | C5AR1 (0.66) | C5AR1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29415612 | 0.87 | CALCA (0.61) | C5AR1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31182780 | 0.87 | C5AR1 (0.66) | C5AR1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30439395 | 0.87 | OPRD1 (0.67) | C5AR1NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364732-B2 | Systems and methods for treatment of hearing using dihexa | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2025-07-22 | — | — | US | claimed |
| US-12186409-B2 | Methods of screening for sortilin binding antagonists | ALECTOR LLC (US) | 2025-01-07 | — | — | US | claimed |
| US-20240424050-A1 | SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXA | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-12-26 | — | — | US | claimed |
| US-20240294603-A1 | SYSTEMS AND METHODS FOR DELIVERY OF SPADIN FOR TREATMENT OF DEPRESSION OR OTHER INDICATIONS | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-09-05 | — | — | US | claimed |
| US-20230033268-A1 | CHIMERIC POLYPEPTIDES AND USES THEREOF | UNIVERSITE D'EVRY VAL D'ESSONNE (FR) | 2023-02-02 | — | — | US | claimed |
| EP-4048786-A1 | CHIMERIC POLYPEPTIDES AND USES THEREOF | Genethon (FR) | 2022-08-31 | — | — | EP | claimed |
| CN-114555808-A | Chimeric polypeptides and uses thereof | 吉尼松公司 | 2022-05-27 | — | — | CN | claimed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| EP-4676914-A1 | MODULATORS OF SORTILIN ACTIVITY | Vesper Bio Aps (DK) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676917-A1 | MODULATORS OF SORTILIN ACTIVITY | Vesper Bio Aps (DK) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676915-A1 | SORTILINE MODULATORS | Vesper Bio Aps (DK) | 2026-01-14 | — | — | EP | disclosed |
| US-20250268854-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | VESPER BIO APS (DK) | 2025-08-28 | — | — | US | disclosed |
| US-12364732-B2 | Systems and methods for treatment of hearing using dihexa | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20230033268-A1 | CHIMERIC POLYPEPTIDES AND USES THEREOF | UNIVERSITE D'EVRY VAL D'ESSONNE (FR) | 2023-02-02 | — | — | US | disclosed |
| CN-115103855-A | Peptides derived from sortilin | 利摩日大学 | 2022-09-23 | — | — | CN | disclosed |
| EP-4048659-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048399-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048786-A1 | CHIMERIC POLYPEPTIDES AND USES THEREOF | Genethon (FR) | 2022-08-31 | — | — | EP | disclosed |
| CN-114555808-A | Chimeric polypeptides and uses thereof | 吉尼松公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220031684-A1 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268854-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | SORT1, NMUR2, NMUR1 | C5AR1 2901/4885NPY1R 576/4885NPY2R 539/4885 |
| US-12364732-B2 | Systems and methods for treatment of hearing using dihexa | PRPH, LTA, SPAST | C5AR1 2155/4885NPY1R 1399/4885NPY2R 1211/4885 |
| US-20240424050-A1 | SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXA | PRPH, LTA, SPAST | C5AR1 2155/4885NPY1R 1399/4885NPY2R 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.